Share

    


Home / Blurb / Discussion Detail

FDA Approves Cemiplimab-rwlc for Advanced Basal Cell Carcinoma

On February 9, the Food and Drug Administration approved the PD-1 inhibitor cemiplimab-rwlc (Libtayo®, Regeneron/Sanofi) as the first immunotherapy treatment indicated for patients with advanced basal cell carcinoma previously treated with a hedgehog pathway inhibitor (HHI) or for whom an HHI is not appropriate. Full approval was granted for patients with locally advanced BCC and accelerated approval was granted for patients with metastatic BCC.

Read the press release

Posted on 2/17/2021